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Abstract
Objective. The objective was to describe the methodology used to develop new response criteria for
adult DM/PM and JDM.
Methods. Patient profiles from prospective natural history data and clinical trials were rated by myositis
specialists to develop consensus gold-standard ratings of minimal, moderate and major improvement.
Experts completed a survey regarding clinically meaningful improvement in the core set measures (CSM)
and a conjoint-analysis survey (using 1000Minds software) to derive relative weights of CSM and candi-
date definitions. Six types of candidate definitions for response criteria were derived using survey results,
logistic regression, conjoint analysis, application of conjoint-analysis weights to CSM and published def-
initions. Sensitivity, specificity and area under the curve were defined for candidate criteria using consen-
sus patient profile data, and selected definitions were validated using clinical trial data.
Results. Myositis specialists defined the degree of clinically meaningful improvement in CSM for minimal,
moderate and major improvement. The conjoint-analysis survey established the relative weights of CSM,
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with muscle strength and Physician Global Activity as most important. Many candidate definitions showed
excellent sensitivity, specificity and area under the curve in the consensus profiles. Trial validation showed
that a number of candidate criteria differentiated between treatment groups. Top candidate criteria def-
initions were presented at the consensus conference.
Conclusion. Consensus methodology, with definitions tested on patient profiles and validated using clin-
ical trials, led to 18 definitions for adult PM/DM and 14 for JDM as excellent candidates for consideration
in the final consensus on new response criteria for myositis.
Key words: dermatomyositis, polymyositis, juvenile dermatomyositis, response criteria, 1000Minds software,
conjoint analysis, hybrid measure, outcome assessment
Rheumatology key messages
. New criteria for minimal, moderate and major response in adult and juvenile myositis were developed.
. The criteria can be used to conduct more efficient drug trials for myositis.
. The criteria are data driven and expert consensus driven, with excellent sensitivity, specificity and face validity for
myositis.
Introduction
Myositis is a heterogeneous, systemic autoimmune dis-
ease requiring multiple outcome measures and composite
response criteria for meaningful clinical trials and thera-
peutic development. Myositis core set activity measures
(CSM) for patients with adult DM/PM or JDM were estab-
lished and validated by the International Myositis
Assessment and Clinical Studies Group (IMACS) and the
Paediatric Rheumatology International Trials Organisation
(PRINTO) [1, 2]. The IMACS CSM include Physician and
Patient/Parent Global Activity, muscle strength measured
by manual muscle testing (MMT), physical function mea-
sured by the (Childhood) HAQ (CHAQ or HAQ),
Extramuscular Global Activity measured using Myositis
Disease Activity Assessment Tool and the most abnormal
serum muscle enzyme (supplementary Table S1, available
at Rheumatology Online) [1, 3]. The PRINTO CSM are simi-
lar but include the Childhood Myositis Assessment Scale
instead of MMT, the global DAS instead of Extramuscular
Global Activity and health-related quality of life (Physical
Summary Score of the Child Health Questionnaire, but not
muscle enzymes) [4, 5]. A clinically meaningful degree of
change in each measure was established previously using
a data-driven consensus process [6].
Preliminary definitions of improvement were de-
veloped through consensus ratings of patient profiles
from natural history studies and therapeutic trials [7, 8].
Those definitions required different combinations of im-
provement in CSM above certain thresholds. However,
they needed validation because they were developed
with few patients, inadequate trial data and some retro-
spective data, and did not include validated criteria for
moderate or major response [9, 10]. Newer methodology
using continuous or hybrid measures of response,
such as conjoint analysis, which was used to develop
classification criteria for other rheumatic diseases
[1115], may increase the sensitivity and specificity of
response criteria. Trial validation is also now required
for final response criteria according to ACR and EULAR
guidelines [16].
Our objective was to use data-driven and expert group
decision-making (consensus) processes to develop new
response criteria for DM/PM and JDM based on the six
CSM of IMACS or PRINTO with data from new cohorts
and clinical trials.
Methods
Overview
Adult and juvenile myositis experts with experience in
using the CSM participated in expert working groups
(supplementary Table S2, available at Rheumatology
Online). They rated clinically meaningful improvement in
the CSM for minimal, moderate and major improvement.
Next, patient profiles were developed from natural history
data and clinical trials [4, 5, 8] (supplementary Fig. S1,
available at Rheumatology Online). Experts then rated
the degree of improvement in patient profiles using the
Delphi technique [17, 18];570% consensus was reached
on minimal, moderate and major improvement. Conjoint-
analysis surveys (using 1000Minds software) [11] were
completed by a subset of experts, and relative weights
of CSM and conjoint analysis-based candidate definitions
for response criteria were derived. Sensitivity, specificity
and area under the curve (AUC) were derived for each
candidate definition by using experts’ consensus ratings
of improvement from patient profiles as a gold standard.
The best-performing candidate definitions were validated
using data from randomized clinical trials, and top candi-
date definitions were taken to the consensus conference
to develop new myositis response criteria for PM/DM and
JDM [10, 19]. The overview and time line of the method-
ology are given in Fig. 1.
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Clinically meaningful improvement in myositis CSM
Adult and juvenile myositis specialists completed an
online Delphi expert survey regarding the degree of
change in each CSM deemed clinically significant, includ-
ing the relative percentage change (defined as final minus
baseline value, divided by baseline, multiplied by 100) and
the absolute change deemed necessary for minimal, mod-
erate and major clinical improvement in a therapeutic trial.
The survey also assessed the minimal number of, and
which, CSM must improve and the maximal number of,
and which, CSM can worsen for a patient to be con-
sidered improved [20].
Adult and paediatric patient profiles
Six natural history studies and five trials were used to
create 270 adult DM/PM patient profiles consisting of
IMACS CSM (supplementary Table S3, available at
Rheumatology Online) [2125] and representing a spec-
trum of from no improvement to major clinical improve-
ment [7, 8]. The Bohan and Peter [26, 27] criteria were
used for classification. The PRINTO prospective cohort
and IMACS natural history study were used to create
299 JDM patient profiles [9, 10]. For each JDM patient,
two profiles were created, one using IMACS and one
using PRINTO CSM. These IMACS and PRINTO profiles
were administered separately to the paediatric experts in
a randomized order. For each profile, the CSM at baseline
and at 412 months’ follow-up, the absolute change and
relative percentage change in each measure were pre-
sented. Raters scored each profile as unchanged or
worse, minimally improved, moderately improved or ma-
jorly improved, and rated the degree of improvement on a
scale of 010 (supplementary Fig. S1, available at
Rheumatology Online). Profiles that did not reach consen-
sus were re-rated, and those without consensus after two
rounds were discarded. Informed patient consents and
institutional review board approvals were obtained for
the original studies and trial by their respective investiga-
tors (supplementary Table S3, available at Rheumatology
Online). In this study, only the de-identified data were
used for development and validation of the response
criteria.
Derivation of candidate definitions
Candidate definitions for response criteria were derived and
tested for sensitivity, specificity and AUC, using the experts’
consensus ratings of patient profiles as the gold standard
(supplementary Table S4, available at Rheumatology
Online). Definitions were examined using relative and abso-
lute percentage change (final minus baseline divided by the
range, multiplied by 100) in CSM. Supplementary Table S4,
available at Rheumatology Online, shows the types of can-
didate definitions. Three types of candidate definitions were
categorical, which included previously published, newly
drafted definitions using Delphi expert survey and weighted
definitions. The previously published and newly drafted cat-
egorical candidate definitions required a certain number of
CSM to improve by varying thresholds while allowing up to
two CSM to worsen by certain thresholds. The weighted
definitions were derived by applying relative weights to the
categorical definitions.
Three other types of candidate definitions were continu-
ous definitions, where total improvement scores are gen-
erated with thresholds for minimal, moderate and major
FIG. 1 Overview of the development of the new response criteria
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improvement. These included logistic regression, CSM-
weighted and conjoint analysis-based definitions (supple-
mentary Table S4, available at Rheumatology Online).
Continuous candidate definitions were hybrid definitions,
where the same definition can be used either as a con-
tinuous outcome measure using the total improvement
score or as a categorical outcome measure using the
thresholds for minimal, moderate and major improvement.
The logistic regression-derived definitions were de-
veloped using randomly selected patient profile data
(two-thirds of the data set) and standard logistic regres-
sion modelling. Expert consensus rating of minimal, mod-
erate and major improvement was the dependent variable
(gold standard), and relative or absolute percentage
changes in each CSM were independent variables. The
cut-off for an optimal sensitivityspecificity trade-off for
improved vs not improved was selected based on the
Youden index [28]. Each model underwent internal valid-
ation using the remaining third of the data set and external
validation using clinical trial data.
Weighted CSM candidate definitions were derived by
multiplying the relative or absolute percentage improve-
ment or worsening in each CSM by its relative weight (de-
veloped in the conjoint-analysis surveys) and then
summing the results of all CSM as total improvement
score.
Conjoint-analysis surveys and candidate definitions
Conjoint-analysis surveys were administered to subgroups
of myositis experts using 1000Minds online software [11].
Experts were presented with pairs of hypothetical patients;
each patient had different levels of improvement in the
same two CSM, assuming other CSM remained the
same. Experts chose which patient had greater improve-
ment, that both had equal improvement, or that the scen-
ario was not possible (supplementary Fig. S2, available at
Rheumatology Online). Based on the rater’s response, all
other hypothetical patients that could be pairwise ranked
were eliminated via the property of transitivity, thereby
significantly reducing the number of scenarios presented.
The Potentially All Pairwise Rankings of All Possible
Alternatives (PAPRIKA) method determined the mean
weights and relative importance of the CSM, using math-
ematical methods based on linear programming [11].
Adult PM/DM conjoint-analysis surveys were adminis-
tered using pairs of patients representing different de-
grees of improvement in IMACS CSM, whereas two
separate surveys representing the same patients were ad-
ministered for JDM using IMACS and PRINTO CSM. For
each CSM, the total potential range of the relative per-
centage improvement was divided into five levels, ensur-
ing that the patient profile data were distributed among
them. Six CSM with five levels resulted in an average of 85
pairwise-ranking questions.
Results from the conjoint-analysis surveys resulted in
development of six conjoint-analysis candidate definitions
that combine continuous improvement scores and cat-
egorical threshold criteria into a single definition (therefore
called a hybrid definition) [29]. Relative weights of CSMs
and their levels of improvement were used to develop a
scoring system such that when all six CSMs are con-
sidered together, the maximal score possible for repre-
senting a patient’s improvement is 100 and the minimal
score is 0. The performance of each candidate criterion
was evaluated by using randomly selected two-thirds of
the patient profile data and by using consensus ratings for
minimal, moderate or major improvement as the gold
standard. Appropriate improvement thresholds in adult
and paediatric patients were selected for each conjoint-
analysis definition based on optimal sensitivity and speci-
ficity (using the Youden index [28]). We simplified the
points given to each level of improvement in CSM by
rounding to the nearest multiple of 2.5, and then we re-
evaluated the sensitivity, specificity and AUC. These
thresholds for minimal, moderate and major improvement
were then validated on the remaining third of the patient
profile data and further validated using clinical trial data.
The thresholds differed for adult PM/DM and JDM for
each candidate definition.
External validation
The candidate definitions that performed well using con-
sensus profile data were externally validated using data
from two controlled trials. The Rituximab in Myositis (RIM)
trial [23], which was used for adult DM/PM patients
(n = 142), was a randomized double-blind placebo-
phased trial where one group received active treatment
early (week 0) and the other group received treatment
late (week 8); primary outcome was time to improvement.
As the trial did not discriminate between treatment arms,
we were unable to determine whether the candidate def-
initions differentiated between early vs late treatments.
The treating physician’s rating of improvement
(07 scale) at 24 weeks in the RIM trial was used for val-
idation, and each point change in physician rating was
considered clinically significant. The MannWhitney U-
test was used to evaluate whether each candidate defin-
ition could differentiate between the treating physician’s
median rating of improvement, if the improvement criteria
were met compared with not met.
For JDM, data from 48 patients in the RIM trial were
used with IMACS CSM, as described for adults. We also
used data from 139 patients in a PRINTO trial of prednis-
one alone vs prednisone combined with either MTX or
CSA, which used both IMACS and PRINTO CSM [19].
For the PRINTO trial, the ability of a candidate definition
to differentiate between treatment arms at 24 weeks was
evaluated using a 2 test to compare the frequency of
patients meeting the candidate response criteria between
the two treatment arms. The candidate definitions for JDM
had to meet performance standards for both IMACS and
PRINTO measures.
After external validation, we selected top candidate def-
initions for response criteria to be evaluated by expert
consensus at the conference held in Paris on 910 June
2014. Adult and paediatric expert groups ranked them
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using a nominal group technique to achieve consensus on
final adult and paediatric response criteria [30, 31].
Results
Clinically meaningful improvement in myositis CSM
Adult and paediatric myositis experts required a median of
20% relative percentage change in each IMACS CSM to
classify adult DM/PM and JDM patients as having minimal
improvement, respectively (Table 1), except for muscle
enzymes, which required greater improvement. The abso-
lute percentage change values were similar, but some-
times of lower magnitude, to classify patients as
improved. Greater degrees of change were required for
moderate and major improvement (Table 1).
For adult DM/PM and JDM, muscle strength was
ranked as the most important CSM, followed by
Physician Global Activity, and must improve for a patient
to be considered clinically improved. Experts suggested
that two to four measures must improve for a patient to be
considered improved. A small degree of deterioration was
allowable in up to two measures.
Inter-rater reliability
There was substantial agreement among all raters
(k= 0.64). There was high agreement between groups of
raters (e.g. adult vs paediatric, rheumatologists vs other
specialists, North America vs other geographical region,
more vs less experienced) for minimal improvement
(k= 0.741.0, 90100% agreement) and major improve-
ment (k= 0.830.93, 9397% agreement). The intra-class
correlation coefficient was high for all raters (0.82) and
among different groups of raters (0.800.83). Among pae-
diatric raters, agreement for both minimal and major im-
provement between IMACS and PRINTO measures was
excellent (8190%, k= 0.67 for both).
Patient profiles
Baseline and follow-up CSM values, as well as relative
and absolute percentage changes in the consensus pro-
files rated as minimally, moderately and majorly improved,
are presented in supplementary Tables S5 and S6, avail-
able at Rheumatology Online. Consensus was achieved
for 157 profiles (48%) as minimally improved, 72 profiles
(22%) as moderately improved and 12 (4%) as majorly im-
proved for adult DM/PM. Likewise, 231 (86%), 155 (58%)
and 63 (24%) profiles were rated as minimally, moderately
and majorly improved, respectively, for both IMACS and
PRINTO JDM cases.
Conjoint-analysis survey
Table 2 shows the relative weights and rank order of im-
portance for each CSM derived from the conjoint-analysis
survey. In the survey of adult myositis experts, the weights
were as follows: baseline weight 1.0 for Patient Global
Activity; MMT, 2.0; Physician Global Activity, HAQ and
Extramuscular Activity, 1.5; and muscle enzyme, 0.5. For
the paediatric IMACS survey, baseline weight 1.0 for
Parent Global Activity; MMT, 3.0; Physician Global
Activity, 2.0; and CHAQ and Extramuscular Activity, 1.5;
and muscle enzyme, 0.5. For the paediatric PRINTO
survey, baseline weight 1.0 for Parent Global Activity;
Childhood Myositis Assessment Scale, 3.5; Physician
Global Activity and DAS, 2.0; and CHAQ and Physical
Summary Score of the Child Health Questionnaire, 1.0.
Based on myositis experts’ preferences for various
CSM, all CSM were ranked in each conjoint-analysis
survey (Table 2), with the rank order paralleling the relative
weights in the CSM.
Candidate definitions for response criteria and their
performance in patient profiles and trial analysis
A total of 287 adult, 284 paediatric IMACS and 312 pae-
diatric PRINTO candidate definitions were derived and
tested for sensitivity, specificity and AUC, using the con-
sensus patient profile ratings as the gold standard (sup-
plementary Table S4, available at Rheumatology Online):
102 adult, 101 paediatric IMACS and 99 PRINTO candi-
date definitions with sensitivity and specificity580%,
AUC50.9 for minimal and AUC50.8 for moderate and
major improvement in the patient profile analysis were
evaluated in trial analysis. For adult DM/PM, 36 candidate
definitions with significant differentiating potential in the
RIM trial and with AUC50.7 were advanced to final se-
lection. For JDM, 29 IMACS and 30 PRINTO candidate
definitions with significant differentiating potential in the
RIM (P< 0.05) and PRINTO trials (P40.057) as well as
AUC50.8 for minimal and AUC50.7 for moderate/
major improvement advanced to final selection. Up to
four top-performing candidate definitions from each cat-
egory were selected for presentation at the consensus
conference. Thus, 18 adult and 14 paediatric candidate
definitions for the response criteria were evaluated at the
consensus conference using nominal group technique.
Results of the consensus conference and final adult and
paediatric myositis response criteria are described in the
final response criteria manuscripts [30, 31].
Discussion
Through the efforts of many experts, by combining data
sets from observational studies and clinical trials and by
using several different statistical approaches, we de-
veloped new candidate definitions for response criteria
for minimal, moderate and major improvement in adult
DM/PM and JDM. Experts’ consensus ratings of a large
number of patient profiles were used as a gold standard to
evaluate the candidate definitions. There was high inter-
rater reliability among the experts.
Clinical trial data from two studies were used to validate
the top-performing candidate definitions. As there was no
difference between the treatment arms in the primary end
point in the RIM trial, we used the treating physician’s
rating of improvement to evaluate the candidate defin-
itions’ performance as the criterion for trial validation.
For the PRINTO trial of new-onset JDM patients [19],
we examined the discriminative power of each candidate
definition by examining the magnitude of difference
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between prednisone-alone vs the combined-treatment
arm (prednisone plus either MTX or CSA).
We used a rigorous, systematic approach to determine
candidate definitions for consideration in a final consen-
sus meeting to select a new response criterion for adult
DM/PM and JDM, based on data-driven development of
candidate definitions and validation with real patient and
trial data in the selection process. One strength of this
approach was that we allowed many different methods
to compete in the data-driven process and in final
expert consensus. We used the results from the first
expert survey and previously published criteria to draft
traditional categorical candidate response criteria that
combined different CSM for minimal, moderate and
major improvement. According to guidance from repre-
sentatives of the US Food and Drug Administration, we
also tested candidate response criteria that required pa-
tient-reported outcome measures to improve or be
weighted more heavily; however, those definitions did
not perform as well as the general definitions. The con-
joint-analysis surveys had been used to weight clinical
and laboratory features differentially to develop scoring
systems, as has been done for new classification criteria
for RA, SSc and gout [12, 3234]. We administered con-
joint-analysis surveys in which experts chose the more
improved hypothetical patient in a pair, defined by the
degree of change in two CSM at a time and involving a
trade-off between them. These expressed choices served
efficiently to reveal each CSM’s relative importance and
were used to differentially weight CSM in the candidate
response criteria. This process also generated continuous
definitions where the continuous improvement score cor-
responded to the magnitude of improvement, with cat-
egorical thresholds for achieving minimal, moderate and
major improvement [29]. Therefore, they are truly hybrid
definitions, in which the same definitions can be used as a
continuous outcome measure by calculating the degree of
improvement, as well as a categorical outcome measure
by using thresholds of improvement. Similar hybrid can-
didate definitions were also developed through traditional
logistic regression approaches, as well as by applying a
relative weight to the degree of change in each CSM. The
improvement score as a continuous outcome measure
could also be used to differentiate between treatment
and placebo by comparing mean improvement scores be-
tween treatment arms, and such scores could potentially
provide more discriminative power, resulting in smaller
sample size requirements in future trials [35]. Lastly, we
selected the top-performing candidate definitions from
each category for presentation at the consensus confer-
ence, as we did not know which response criterion struc-
ture would have better face validity and acceptability to
TABLE 1 Results of the core set measure surveya
Minimal improvement Moderate improvement Major improvement
Core set measure
Relative
percentage
changeb
Absolute
percentage
changec
Relative
percentage
changeb
Absolute
percentage
changec
Relative
percentage
changeb
Absolute
percentage
changec
Adult
MD global 20 (1530) 20 (1020) 30 (2540) 35 (2040) 50 (4070) 50 (3070)
Patient/parent global activity 20 (1530) 20 (1530) 30 (2540) 35 (2540) 50 (4060) 50 (3560)
MMT 20 (1020) 13 (1020) 30 (2040) 31 (1044) 50 (3070) 50 (2363)
HAQ 20 (1525) 33 (1033) 30 (3040) 33 (2050) 50 (4060) 67 (3367)
ExtraMusc 20 (1525) 20 (1020) 30 (2540) 40 (2040) 50 (3060) 50 (3060)
Enzymed 30 (2040) 20 (1020) 40 (3050) 30 (2050) 55 (5080) 50 (30100)
Paediatric
MD Global 20 (2030) 20 (2020) 40 (3050) 40 (2440) 60 (5070) 50 (4070)
Patient/parent global activity 20 (2030) 20 (2030) 40 (3050) 30 (3050) 60 (5070) 60 (4070)
MMT 20 (1530) 19 (1225) 40 (2550) 36 (2345) 50 (5070) 50 (3366)
CHAQ 20 (2030) 17 (1333) 40 (3050) 33 (2033) 60 (5070) 67 (4067)
ExtraMusc 20 (2030) 20 (2030) 30 (3050) 30 (3050) 50 (5070) 55 (5070)
Enzymed 30 (2350) 25 (1530) 50 (3060) 50 (3050) 70 (5080) 60 (5075)
CMAS 20 (1530) 13 (1019) 40 (2550) 20 (1938) 50 (5070) 49 (2958)
DAS 20 (2030) 20 (2025) 30 (3050) 40 (2550) 50 (5070) 60 (4075)
CHQ-PF50 20 (2030) 15 (1325) 40 (3050) 25 (2538) 55 (5070) 40 (3853)
aResults are presented as the median (interquartile range). They show the degree of change deemed clinically relevant by an
expert panel of myositis clinicians for minimal, moderate and major improvement for adult (DM/PM) and paediatric (JDM) groups.
bRelative percentage change = [(finalbaseline value)/baseline value]100. cAbsolute percentage change = [(finalbaseline
value)/potential range for test]  100. dEnzyme (expressed as percentage of upper limits of normal) details for patients include
aldolase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and creatine kinase. CHAQ: Childhood
Health Assessment Questionnaire; CHQ-PF50: physical summary score of the Child Health QuestionnaireParent Form 50;
CMAS: Childhood Myositis Assessment Scale; ExtraMusc: extramuscular global activity score; MD Global: physician global
activity score; MMT: Manual Muscle Test.
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expert physicians. The results of the consensus confer-
ence are published elsewhere [30, 31].
We encountered several issues while developing these
new response criteria. First, the CSM have varying relative
importance, with muscle strength followed by Physician
Global Activity as the most important measures. However,
muscle strength changed much less than other CSM, par-
ticularly in adult patients, but was nevertheless con-
sidered by the experts to be important. Consequently,
trials that rely on improvement in muscle strength as a
sole primary end point [36, 37] would probably not suc-
ceed in demonstrating improvement, because strength
changes very little in most adult DM/PM patients.
Second, in developing new response criteria, we sepa-
rated the IMACS and PRINTO CSM for JDM and tested
these candidate definitions separately. However, because
several CSM overlap, we paired these candidate defin-
itions and found that they showed similar performance
characterstics, thus allowing the interchange of IMACS
or PRINTO CSM in a final response criterion. While de-
veloping preliminary response criteria, we sought candi-
date definitions that performed well for both adult DM/PM
and JDM. However, in this new process, we separated
adult DM/PM and JDM candidate definitions for response
criteria and conducted the analyses in parallel, maintain-
ing separate data sets and expert groups. In this way, the
best-performing response criteria could be established for
adult DM/PM as well as JDM, and either distinct or the
same criteria could be established as the response criter-
ion for combined adult DM/PM and JDM trials.
Potential limitations of this work include over-fitting the
models and the increased likelihood of overestimating the
performance owing to the large number of candidate
definitions considered. We decreased the likelihood of se-
lecting a low-performing model by means of both internal
and external validation. Another limitation is that the deci-
sions made at various stages of development of the cri-
teria were influenced by several considerations, including
available resources and data sets, statistical properties of
different approaches used, methods used for reaching
consensus and experts’ preferences regarding similarly
performing definitions. Moreover, most of the CSM are
subjective, and although there is need to develop better
objective CSM in myositis, they represented the most vali-
dated and accepted CSM currently available to develop
data- and consensus-driven composite response criteria.
Lastly, improvement thresholds of minimal, moderate and
major response were based on expert consensus as a
gold standard and not on quality of life or other outcomes,
such as survival.
In summary, through several online consensus-rating
exercises and statistical approaches using large, pooled
natural history and trial data sets, we developed new can-
didate definitions for response criteria for minimal, moder-
ate and major improvement for adult DM/PM and JDM.
These candidate definitions all perform acceptably, and
their structure is similar—but not identical—to myositis
expert opinion recommendations on the requirements for
clinical improvement. A consensus selection of the top re-
sponse criteria for myositis based on performance charac-
teristics, face validity and acceptability was made at
the consensus conference [30, 31]. Uniform and consen-
sus-driven, validated response criteria in myositis, along
with new and improved classification criteria that are
being developed [38], may lead to better clinical trials in
myositis.
TABLE 2 Rounded weightsa and relative rank of importance of each core set measure
Adult IMACS Paediatric IMACS Paediatric PRINTO
Core set measure Weight Relative rank Weight Relative rank Weight Relative rank
MD global activity 1.5 2 2.0 2 2.0 2
Patient/parent global activity 1.0 5 1.0 6 1.0 4
MMT8 2.0 1 3.0 1 N/A N/A
CMAS N/A N/A N/A N/A 3.5 1
HAQ/CHAQ 1.5 4 1.5 4 1.0 3
Extramuscular activity 1.5 3 1.5 3 N/A N/A
DAS N/A N/A N/A N/A 2.0 2
Enzyme 0.5 6 1.0 5 N/A N/A
CHQ-PhS N/A N/A N/A N/A 1.0 5
aWeights were generated based on the results of the 1000Minds survey. Weights were rounded to the nearest multiple of 0.5
from their original weightings and were derived as the average weights of all adult or paediatric experts participating in the
conjoint analysis surveys, with higher weight indicating experts’ stronger importance associated with a particular core set
measure in defining the degree of improvement in patients. Relative rank is based on mean relative importance scores, which
consist of the average rank order of core set measures among experts participating in the conjoint analysis surveys, with lower
scores indicating a higher degree of importance of that measure in determining whether a patient is improved or not. CHAQ:
Childhood Health Assessment Questionnaire; CHQ-PhS: physical summary score of the Child Health Questionnaire; CMAS:
Childhood Myositis Assessment Scale; IMACS: International Myositis Assessment and Clinical Studies Group; MMT8: Manual
Muscle Test on 8 muscles; N/A: not applicable; PRINTO: Paediatric Rheumatology International Trials Organisation.
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